BIOS Fund I, LP - 28 Oct 2026 Form 4 Insider Report for ACTUATE THERAPEUTICS, INC. (ACTU)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ACTU
Reported as of: 28 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Oct 2026, 15:37:14 UTC
Source filing: View source filing
Reporting owner signature: Bios Fund I, LP By: Bios Equity Partners, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact

Filing notes and source

Key filing fact

BIOS Fund I, LP filed Form 4 for ACTUATE THERAPEUTICS, INC. (ACTU) on 30 Oct 2026.

Key facts

This page summarizes BIOS Fund I, LP's Form 4 filing for ACTUATE THERAPEUTICS, INC. (ACTU).
13 reported transactions and 130 derivative rows are listed below.
Accepted by SEC: 30 Oct 2026, 15:37.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (10)

CIK 0001697316 Primary reporting owner

BIOS Fund I, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund I, LP By: Bios Equity Partners, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0002028708

Bios 2024 Co-Invest, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN, SUITE 400, FORT WORTH
Signature: Bios 2024 Co-Invest, LP By: Bios Equity COF, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001771378

BIOS Actuate Co-Invest I, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN, SUITE 400, FORT WORTH
Signature: Bios Actuate Co-Invest I, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001825398

BIOS Actuate Co-Invest II, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN, SUITE 400, FORT WORTH
Signature: Bios Actuate Co-Invest II, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001956704

Bios Actuate Co-Invest III, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN, SUITE 400, FORT WORTH
Signature: Bios Actuate Co-Invest III, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001988639

Bios Clinical Opportunity Fund, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN, SUITE 400, FORT WORTH
Signature: Bios Clinical Opportunity Fund, LP By: Bios Equity COF, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001700297

BIOS Fund I QP, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund I QP, LP By: Bios Equity Partners, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001728851

BIOS Fund II NT, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund II NT, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001716869

BIOS Fund II QP, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund II QP, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

CIK 0001714576

BIOS Fund II, LP

Relationship: Director, 10%+ Owner
Address: C/O BIOS EQUITY PARTNERS, 1751 RIVER RUN SUITE 400, FORT WORTH
Signature: Bios Fund II, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact
Signature date: 30 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +64,995
Change %
Price: $0.000000^*
Shares after: 64,995
Date: 28 Oct 2026
Ownership: Directly held by Bios 2024 Co-Invest, LP
Underlying class: Common Stock
Underlying amount: 64,995
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +87,743
Change %
Price: $0.000000^*
Shares after: 87,743
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest I, LP
Underlying class: Common Stock
Underlying amount: 87,743
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +682,885
Change %
Price: $0.000000^*
Shares after: 682,885
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest II, LP
Underlying class: Common Stock
Underlying amount: 682,885
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +194,984
Change %
Price: $0.000000^*
Shares after: 194,984
Date: 28 Oct 2026
Ownership: Directly held by Bios Actuate Co-Invest III, LP
Underlying class: Common Stock
Underlying amount: 194,984
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +368,304
Change %
Price: $0.000000^*
Shares after: 368,304
Date: 28 Oct 2026
Ownership: Directly held by Bios Clinical Opportunity Fund, LP
Underlying class: Common Stock
Underlying amount: 368,304
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +47,972
Change %
Price: $0.000000^*
Shares after: 47,972
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I QP, LP
Underlying class: Common Stock
Underlying amount: 47,972
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,018
Change %
Price: $0.000000^*
Shares after: 82,018
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund I, LP
Underlying class: Common Stock
Underlying amount: 82,018
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +36,056
Change %
Price: $0.000000^*
Shares after: 36,056
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II NT, LP
Underlying class: Common Stock
Underlying amount: 36,056
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +269,342
Change %
Price: $0.000000^*
Shares after: 269,342
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II QP, LP
Underlying class: Common Stock
Underlying amount: 269,342
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +82,454
Change %
Price: $0.000000^*
Shares after: 82,454
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund II, LP
Underlying class: Common Stock
Underlying amount: 82,454
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +133,073
Change %
Price: $0.000000^*
Shares after: 133,073
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III NT, LP
Underlying class: Common Stock
Underlying amount: 133,073
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +824,012
Change %
Price: $0.000000^*
Shares after: 824,012
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III QP, LP
Underlying class: Common Stock
Underlying amount: 824,012
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

ACTU transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +126,162
Change %
Price: $0.000000^*
Shares after: 126,162
Date: 28 Oct 2026
Ownership: Directly held by Bios Fund III, LP
Underlying class: Common Stock
Underlying amount: 126,162
Exercise price: $0.5325
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Pursuant to a letter agreement, dated as of October 2, 2026 and amended on October 16, 2026 (the "Letter Agreement"), between Actuate Therapeutics, Inc. (the "Issuer") and Bios Partners, L.P., on behalf of certain Bios entities (the "Bios Entities"), the Bios Entities agreed to a two-year lock-up of securities of the Issuer beneficially owned by them. In consideration thereof, the Issuer agreed to issue to the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock, par value $0.000001 per share (the "Common Stock"), at an exercise price of $0.5325 per share (the "Warrants"). The Warrants were issued at the closing of the Issuer's public offering.

Footnote F2

A Warrant may be exercised only during the period ("Exercise Period") commencing on October 28, 2026 and terminating at 5:00 P.M., New York time on October 28, 2031 ("Expiration Date"). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date.

Footnote F3

Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest.

Footnote F4

Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.

Footnote F5

The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.

SEC remarks

This Form 4 is the second of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons. The first Form 4 was filed by Bios Fund I, LP.